GlobeImmune's lead infectious disease product, GI-5005, is scheduled to begin a randomized Phase 2 clinical trial in combination with standard of care in patients with chronic hepatitis C infection at over 40 US centers in the second half of 2007. The Company's lead oncology product GI-4000 is currently being studied in a placebo-controlled Phase 2 clinical trial in patients with resectable pancreas cancer.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

1450 Infinite Dr.
Louisville, CO 80027
USA

Phone

(303) 625-2700

Website

www.globeimmune.com

Email Address

[email protected]

Overview

GlobeImmune is developing Tarmogen product candidates to treat cancer and infectious diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Timothy Rodell

VP - Bus. Development

Kirk Christoffersen

VP - Finance

Jeffrey Dekker

Browse more venture capital transactions:

Prev: 9/26/2007: Renaissance Lighting venture capital transaction
Next: 9/26/2007: LeisureLink venture capital transaction

Share this article

News on VC Transactions

We document all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary